WT1基因rs16754多态性与急性髓系白血病患者临床特征及预后关系的研究

OBJECTIVE: To explore the relationship between WT1 rs16754 polymorphism and clinical features and prognosis in patients with acute myeloid leukemia (AML). METHODS: Bone marrow samples of 115 newly diagnosed AML patients and peripheral blood samples of 177 healthy controls were collected from the Second Hospital of Shanxi Medical University from January 2010 to December 2013. The genotype of rs16754 was screened by high-resolution melting (HRM) and validated by direct sequencing. The association between the single nucleotide polymorphism (SNP) and the risk, clinical features, remission and survival state of AML patients was analyzed retrospectively. RESULTS: This polymorphism was not associated with risk for AML (P=0.296), the GA/AA group and GG group had no significant difference in gender, age, clinical features and remission rate of chemotherapy (P>0.05), the percentage of bone marrow cells in GA/AA group was higher than that in GG group (P=0.025). The survival state of 99 patients were followed up, single factor analysis found that the difference of the overall survival rate was statistically significant (P=0.035) between the two groups, the rate of GA/AA group was higher than that of the GG group. Multivariate analysis showed that the A allele was an independent prognostic factor for AML patients and the mortality risk of GA/AA patients were higher (HR=1.681, 95% CI 1.046–2.700, P=0.032). CONCLUSION: WT1 rs16754 polymorphism is associated with the prognosis of AML, and can be used as one of the indicators for the prognosis of AML patients.